Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DBV 135

Next Previous
Drug Profile

DBV 135

Alternative Names: Cows milk allergy immunotherapy; DBV-135; Viaskin Milk

Latest Information Update: 28 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DBV Technologies
  • Developer DBV Technologies; The Childrens Hospital of Philadelphia
  • Class Anti-inflammatories; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Eosinophilic oesophagitis; Milk hypersensitivity

Most Recent Events

  • 28 Sep 2021 Milk allergy immunotherapy is still in phase II development for Milk hypersensitivity (In adolescents, In children) in USA and Canada (DBV Technologies pipeline, September 2021)
  • 28 Sep 2021 Phase II development is still ongoing for eosinophilic oesophagitis in USA ((DBV Technologies pipeline, September 2021)
  • 01 Feb 2021 DBV Technologies completes a phase I/II (MILES) trial in Milk-hypersensitivity (In adolescents, In children) in Canada and the US (NCT02223182)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top